CD4 and metastatic melanoma: In these samples, all patients presented with an increase of CD4 + lymphocyte tissue infiltration and patients with SD or PR presented with a higher increase of CD3 + and CD4 + lymphocytes compared to no responder patients.76,77 Another phase 1 explored the KW-2871 activity in 17 metastatic melanoma patients with increasing doses (20, 40, 60, and 80 mg/m2).